Guggenheim lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $77 from $78 and keeps a Buy rating on the shares. The firm is ...

For many years, the pharmaceutical business concentrated mostly on blockbuster medications, which are cures for common ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $60.0 for SpringWorks Therapeutics, spanning the last ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...

The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...

SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...

SpringWorks Therapeutics Inc (NASDAQ:SWTX) is set to release its Q4 2024 earnings on February 20, 2025. The consensus estimate for Q4 2024 revenue is $59.12 million, and the earnings are expected to ...

Just over two years after establishing desmoidtumors.com, the drugmaker is teaming with Jennifer Fisher to empower patients.

The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...